We are thrilled to announce that CRIO, a leading provider of eSource and other eClinical technologies, received a significant investment from The Riverside Company, a global growth oriented private equity firm.
CRIO’s industry-leading eClinical platform is designed to streamline research at the site-level, with fully integrated eSource, site CTMS, eConsent, EDC, remote monitoring, and source data verification solutions. Its innovative, integrated direct data capture solution reduces the cost and increases the speed of conducting a clinical trial while improving data quality.
The investment will provide for further expansion of CRIO’s capabilities, which directly challenge incumbent methods of capturing clinical trial data and managing research site workflows.
You can read the full press release here.
